Postpartum cells derived from placental tissue, and methods of making and using the same
First Claim
1. A method of producing a population of placenta-derived cells by expanding an isolated human placenta-derived cell in culture and obtaining a homogenous population of placenta-derived cells,wherein said isolated human placenta-derived cell is obtained from human postpartum placenta substantially free of blood, andwherein said cell population self-renews and expands in culture, is multipotent, and has the following characteristics:
- a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2, HLA-A,B,C, and granulocyte chemotactic protein-2 (GCP-2);
b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G or HLA-DR-DP,DQ;
c) does not produce GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry;
d) expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA and renin; and
e) has the ability to undergo at least 40 population doublings in culture.
0 Assignments
0 Petitions
Accused Products
Abstract
Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.
-
Citations
15 Claims
-
1. A method of producing a population of placenta-derived cells by expanding an isolated human placenta-derived cell in culture and obtaining a homogenous population of placenta-derived cells,
wherein said isolated human placenta-derived cell is obtained from human postpartum placenta substantially free of blood, and wherein said cell population self-renews and expands in culture, is multipotent, and has the following characteristics: -
a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2, HLA-A,B,C, and granulocyte chemotactic protein-2 (GCP-2); b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G or HLA-DR-DP,DQ; c) does not produce GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry; d) expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA and renin; and e) has the ability to undergo at least 40 population doublings in culture. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
Specification